Market Overview

NF-kB Inhibitors - 2018 Pipeline Insights with Analysis by Development Stage, Mechanism of Action, Route of Administration and Molecule Type -


The "NF-kB
Inhibitors- Pipeline Insights, 2018"
report has been added to's

This report outlays comprehensive insights of present scenario and
growth prospects across NF-kB Inhibitors.

A detailed picture of the pipeline landscape is provided with summation
of data from multiple sources with complete analysis by development
stage, mechanism of action, route of administration and molecule type.

This report provides detailed analysis of 12+ active products with more
than 10 companies involved. Some of the key players include AMG0101 of
AnGes MG and Bardoxolone methyl of Reata Pharmaceuticals, and BIIB098 of

Products covered by Phase

  • Phase III, Phase II, Phase I
  • Pre-clinical
  • Inactive (Dormant and Discontinued)

Overview of pipeline development activities for NF-kB Inhibitors

  • Pipeline analysis of therapeutic drugs include but are not limited to
    drug description and development activities focusing on clinical and
    pre-clinical results, designations, collaborations & licensing deals,
    grants, technology and patent details.
  • Therapeutic segmentation of products for NF-kB Inhibitors.
  • The report comprises of comparative pipeline therapeutics assessment
    by development stage, therapy type, molecule type, and administration
    route across this mechanism.


  • Provides an overview of therapeutic pipeline activity for NF-kB
    Inhibitors across the complete product development cycle including all
    clinical and non-clinical stages
  • It comprises of detailed profiles of NF-kB Inhibitors therapeutic
    products with key coverage of developmental activities including
    licensing & collaboration deals, patents issued, designations,
    technologies and chemical information
  • Therapeutic assessment of the active pipeline products by stage,
    product type, molecule type, and route of administration
  • Coverage of dormant and discontinued pipeline projects across NF-kB

Key Topics Covered

  1. Executive Summary
  2. Overview
  3. Introduction
  4. Structure
  5. Mechanism of Action
  6. Inducers
  7. Repressors
  8. Clinical Significance
  9. NF-kB Inhibitors
  10. Pipeline Therapeutics (Active Products)
  11. Pipeline Therapeutics (Inactive Products)
  12. Comparative Analysis
  13. Late Stage Products (Phase III)
  14. Comparative Analysis
  15. AMG0101: AnGes MG
  16. Product Description
  17. Research and Development
  18. Product Development Activities
  19. The list continues.
  20. Mid Stage Products (Phase II)
  21. Comparative Analysis
  23. Product Description
  24. Research and Development
  25. Product Development Activities
  26. The list continues.
  27. Early Stage Products (Phase I)
  28. Comparative Analysis
  29. Pre-clinical Stage Products
  30. Comparative Analysis
  31. Therapeutic Assessment: Active Products
  32. Assessment by Stage and Product Type
  33. Assessment by Route of Administration
  34. Assessment by Stage and Route of Administration
  35. Assessment by Molecule Type
  36. Assessment by Stage and Molecule Type
  37. Inactive Products (Dormant & Discontinued Products)
  38. Comparative Analysis
  39. Appendix

Companies Featured

  • AnGes MG
  • Catabasis Pharmaceuticals
  • Constellation
  • Dendright
  • Incuron
  • MedDay Pharmaceutical
  • Neurmedix
  • Realm Therapeutics
  • Reata Pharmaceuticals
  • Tracon Pharmaceuticals

For more information about this report visit

View Comments and Join the Discussion!